3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Thoracic
4
Gastrointestinal
3
Gynecologic
2
Genitourinary
2
Dermatologic
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Conditions
Sarcoma
43
Melanoma
19
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Breast Neoplasms
9
Glioblastoma
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Gliosarcoma
7
Lung Neoplasms
6
Histiocytoma, Malignant Fibrous
6
Carcinoma, Renal Cell
6
Osteosarcoma
5
Liposarcoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Sarcoma, Synovial
4
Sarcoma, Kaposi
4
Neurofibrosarcoma
4
Lymphoma
4
Hemangiosarcoma
4
Carcinoma, Merkel Cell
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Interventions
Nivolumab
2
Imatinib Mesylate
2
pembrolizumab
1
Surveys and Questionnaires
1
Specimen Handling
1
Quality of Life
1
Protons
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Immunotherapy
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
pembrolizumab
×
Sarcoma
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled